{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50"},{"groupId":"OG001","value":"53"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"108"}],"units":"Participants"}],"description":"Improvement in RBC transfusion independence as per International Working Group for MDS (IWG-MDS) criteria. RBC transfusion independence was defined as having received 0 units of RBC transfusions during at least 8 consecutive weeks after randomization. The number of participants was shown in only those with transfusion dependence at baseline (BL).","groups":[{"description":"Participants were randomized to sabatolimab plus Azacitidine","id":"OG000","title":"Sabatolimab (MBG453) + Azacitidine"},{"description":"Participants were randomized to placebo plus Azacitidine","id":"OG001","title":"Placebo + Azacitidine"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants of the full analysis set (FAS) who were RBC transfusion dependent at baseline.","reportingStatus":"POSTED","timeFrame":"up to approx. 52 months","title":"Number of Participants Who Become Red Blood Cells (RBC) Transfusion Independent After Randomization","type":"SECONDARY","unitOfMeasure":"Participants"}